J Korean Med Sci.  2014 Sep;29(9):1205-1211. 10.3346/jkms.2014.29.9.1205.

Drug Survival Rates of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis

Affiliations
  • 1Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School & Hospital, Gwangju, Korea. shinseok@chonnam.ac.kr

Abstract

We investigated the compliance of Korean patients using tumor necrosis factor (TNF) inhibitors to treat rheumatoid arthritis (RA) and ankylosing spondylitis (AS), and identified potential predictors associated with treatment discontinuation. The study population comprised 114 RA and 310 AS patients treated with TNF inhibitors at a single tertiary center for at least 1 yr from December 2002 to November 2011. Of the 114 RA patients, 64 (56.1%) discontinued their first TNF inhibitors with a mean duration of 18.1 months. By contrast, 65 of 310 patients (21.0%) with AS discontinued their first TNF inhibitors, with a mean duration of 84 months. Although the survival rate did not differ among the three TNF inhibitors in the AS patients, the etanercept group had a lower discontinuation rate than the infliximab group in the RA patients. In addition, RA patients who received corticosteroids in combination with TNF inhibitors were more likely to discontinue their TNF inhibitors. The independent predictors of drug discontinuation in AS patients were male gender and complete ankylosis on radiographs of the sacroiliac joint. Our results provide further evidence that real-life treatment outcomes of RA and AS patients may be different from those observed in randomized clinical trials.

Keyword

Arthritis, Rheumatoid; Spondylitis, Ankylosing; TNF Inhibitor; Survival

MeSH Terms

Adult
Aged
Antibodies, Monoclonal/therapeutic use
Antibodies, Monoclonal, Humanized/therapeutic use
Antirheumatic Agents/*therapeutic use
Arthritis, Rheumatoid/*drug therapy/mortality
Cohort Studies
Female
Follow-Up Studies
Humans
Immunoglobulin G/therapeutic use
Male
Middle Aged
Proportional Hazards Models
Receptors, Tumor Necrosis Factor/therapeutic use
Sex Factors
Spondylitis, Ankylosing/*drug therapy/mortality/radiography
Tertiary Care Centers
Treatment Refusal
Tumor Necrosis Factors/*antagonists & inhibitors/metabolism
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antirheumatic Agents
Immunoglobulin G
Receptors, Tumor Necrosis Factor
Tumor Necrosis Factors
Full Text Links
  • JKMS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error